AZNAstraZenecaRunning, no new patients
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 607 (final count)
- Started
- Sep 12, 2022
- Main results expected
- Jul 15, 2027
- Fully finished
- Apr 10, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: Until progressive disease (PD) [assessed Up to 6.6 Years].
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05057494 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC